Navigation Links
Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
Date:1/8/2012

at 1-888-477-2403 (available Monday-Friday 9 a.m. to 8 p.m. Eastern Time) for information on how to return the affected products and receive a full refund. For more detailed information, consumers should visit our website at www.novartisOTC.com as of January 9, 2012. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these drug products.

Adverse events that may be related to the use of these products may be reported to FDA's MedWatch Adverse Event Reporting Program either online, by regular mail or by fax:

  • Online: www.fda.gov/medwatch/report.htm
  • Regular Mail: use postage-paid FDA form 3500 available at:
    www.fda.gov/MedWatch/getforms.htm.
    Mail to MedWatch, FDA, 5600 Fishers Lane, Rockville, MD  20852-9787
  • Fax: 1-800-FDA-0178
  • These actions announced today, highlight the strong Novartis commitment to a single quality standard for the Novartis Group. The Novartis Group is making the necessary investments and committing the right resources to ensure these are implemented across the entire Novartis Group network. The high quality of Novartis products and operations has been critical to building the Novartis Group reputation over the past 15 years. Novartis Group is committed to ensuring the highest standard for patients who rely on our products and medicines.

    Novartis Consumer Health Inc. plans to gradually resume operations at its Lincoln, NE site following implementation of planned improvements and in agreement with the FDA. The Novartis Consumer Health Inc. Lincoln, NE facility produces a variety of products mainly for the US market with annual sales value of less than 2% of Novartis Group sales. At this stage, it is not possible to determine when the plant will resume
    '/>"/>

    SOURCE Novartis Consumer Health, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
    2. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
    3. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
    4. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
    5. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
    6. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
    7. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
    8. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
    9. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
    10. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
    11. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
    (Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
    (Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
    Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
    ... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
    ... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
    Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
    (Date:6/29/2015)... Milwaukee, Wisconsin (PRWEB) , ... June 29, 2015 ... ... thrilled with the news that the European Medicines Agency (EMA) has granted accelerated ... , “Melanoma remains a global public health threat and the approval of nivolumab ...
    (Date:6/29/2015)... , ... June 29, 2015 , ... ... products, announces the Fresh Plus Diaper, a baby invention that makes parenthood less ... is projected to reach a market value of USD 52.2 billion in 2017," ...
    (Date:6/29/2015)... ... June 29, 2015 , ... ... filed against C.R. Bard, Inc. and Ethicon, Inc. continue to move forward in ... Case Management Conference is to be convened on Thursday, July 23rd at 12:00 ...
    (Date:6/29/2015)... ... 2015 , ... OR Manager announced Monday the launch of an enhanced ... a redesigned logo and weekly eLetter. The website contains the same informational articles, products, ... to navigate. , In addition to a refreshed look, http://www.ormanager.com now ...
    (Date:6/29/2015)... MI (PRWEB) , ... June 29, 2015 , ... Celebrities ... perfect ten and have flawless skin all summer long and beyond. People don’t ... simple steps to slow the aging process, maintain an even skin tone, avoid breakouts, ...
    Breaking Medicine News(10 mins):Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 2Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 5Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4Health News:OR Manager Launches New Website 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 3
    ... terms, anesthesia-associated mortality has risen again. The reasons for ... older and multimorbid patients and surgical procedures that would ... result of a selective literature review of Andr Gottschalk,s ... current issue of Deutsches rzteblatt International ( ...
    ... of The Gerontologist urges aging ... in their work. The publication also identifies research priorities ... in addition to providing several strategies that scholars can ... that non-white minorities will make up 42 percent of ...
    ... News) -- New research links medical problems caused by blood ... storage. The findings suggest that a better way to store ... high amounts of blood can lead to complications, including infection, ... Mark T. Gladwin in a news release from Wake Forest ...
    ... (NNI) released four reports that are the result ... issues in the nanotechnology environmental, health, and safety ... part of an ongoing strategy to coordinate nanotechnology-related ... and the Federal Government to share the latest ...
    ... , THURSDAY, July 21 (HealthDay News) -- The ... exhaustion, increases with age, experts at the U.S. National Institute ... researchers explained, they are less able to adapt to high ... a result, the heat might exacerbate any medical conditions they ...
    ... July 20 (HealthDay News) -- In a long-awaited move, ... the blood thinner Brilinta (ticagrelor) for use in patients ... for heart attack and death. Acute coronary syndromes ... attack linked to lowered blood flow to the heart, ...
    Cached Medicine News:Health News:Minority participants crucial to effective aging studies 2Health News:Blood Stored Too Long May Threaten Patient Safety 2Health News:NNI releases 4 workshop reports from the nanoEHS Series 2Health News:Elderly at Greater Risk for Heat Stroke, Experts Warn 2Health News:FDA Approves Blood Thinner Brilinta for Heart Patients 2
    Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
    Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
    Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
    Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
    Medicine Products: